Compare Novavax Inc (NVAX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Summit Therapeutics Inc — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Summit Therapeutics Inc trades at $14.57 (market cap $10.48B). The key difference: Summit Therapeutics Inc is far larger — about 8.1× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SMMT | |
|---|---|---|
Market Cap | $1.30B | $10.48B |
Sector | Health | Health |
52-Week High | $11.19 | $29.32 |
52-Week Low | $6.22 | $13.05 |
Enterprise Value | $800.50M | $9.90B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
